| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.001 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |